Biosimilars Market by Product (Recombinant Non-Glycosylated Proteins (Insulin, rHGH, Interferon), Glycosylated (mAb, EPO), Peptides (Glucagon, Calcitonin)), Manufacturing Type (In-house, Contract), Disease (Oncology, Autoimmune) - Global Forecast to 2023
By: marketsandmarkets.com
Publishing Date: April 2018
Report Code: BT 2160
The biosimilars market is expected to reach USD 23.63 Billion by 2023 from USD 4.49 Billion in 2017, at a CAGR of 31.7%. The base year for this study is 2017 and the forecast period is 20182023.
The objectives of this study are as follows:
- To define, describe, segment, and forecast the biosimilars market by product, type of manufacturing, disease, and region
- To forecast the size of the market with respect to four main regional segments, namely, North America, Europe, Asia, and the Rest of the World (RoW)
- To provide detailed information regarding the major factors influencing the growth of the market (drivers, restraints, opportunities, and challenges)
- To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
- To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To profile key players and comprehensively analyze their market shares and core competencies in terms of market developments and growth strategies
- To track and analyze competitive developments such as collaborations, regulatory approvals, partnerships, acquisitions, and product launches in the biosimilars market
Research Methodology
Top-down and bottom-up approaches were used to estimate and validate the size of the market and to estimate the size of various other dependent submarkets. The overall market size was used in the top-down approach to estimate the sizes of other individual submarkets (mentioned in the market segmentation by product, type of manufacturing, and disease) through percentage splits from secondary and primary research. The bottom-up approach was also implemented (wherever applicable) for data extracted from secondary research to validate the market segment revenues obtained. Various secondary sources such as World Health Organization, US Food and Drug Administration, Centers for Disease Control and Prevention, and European Commission have been used to identify and collect information useful for this extensive commercial study of the biosimilars market. Primary sources such as experts from related industries and suppliers have been interviewed to obtain and verify critical information as well as to assess prospects of the biosimilars market. The breakdown of profiles of primaries is shown in the figure below:
To know about the assumptions considered for the study, download the pdf brochure
The key players in the biosimilars market include are Pfizer (US), Sandoz (Germany), Teva Pharmaceuticals (Israel), Amgen (US), Biocon (India), Dr. Reddys Laboratories (India), Celltrion (South Korea), and Samsung Biologics (South Korea).
Target Audience for this Report:
- Biopharmaceutical drug manufacturers (biosimilars and biologics)
- Private equity companies and venture capital firms
- Healthcare service providers (hospitals and independent physicians)
- Health insurance payers
- Research and consulting service firms
- Contract research organizations (CROs)
- Contract manufacturing organizations (CMOs)
- Pharmaceutical and medical associations
Scope of the Report:
This report categorizes the biosimilars market into the following segments:
- Biosimilars Market, By Product
- Recombinant Non-glycosylated Proteins
- Insulin
- Recombinant Human Growth Hormone
- Granulocyte Colony-stimulating Factor
- Interferons
- Interferon-Beta
- Interferon-Alpha
- Recombinant Glycosylated Proteins
- Erythropoietin
- Monoclonal Antibodies
- Rituximab
- Infliximab
- Adalimumab
- Other Monoclonal Antibodies
- Follitropin
- Recombinant Peptides
- Glucagon
- Calcitonin
- Recombinant Non-glycosylated Proteins
- Biosimilars Market, By Type of Manufacturing
- In-house Manufacturing
- Contract Manufacturing
- Biosimilars Market, By Disease
- Oncology
- Blood Disorders
- Chronic Diseases
- Autoimmune Diseases
- Growth Hormone Deficiency
- Infectious Diseases
- Other Diseases
- Biosimilars Market, By Region
- North America
- US
- Canada
- Europe
- Germany
- UK
- France
- Italy
- Spain
- RoE (Rest of Europe)
- Asia
- China
- India
- Japan
- South Korea
- RoA (Rest of Asia)
- Rest of the World
- Latin America
- Pacific and Oceania
- Middle East and Africa
- North America
Customization Options:
- Company Information: Detailed company profiles of five or more market players
- Opportunities Assessment: A detailed report underlining the various growth opportunities presented in the market
Table of Contents
1 Introduction (Page No. - 16)
1.1 Objectives of the Study
1.2 Market Definition
1.3 Market Scope
1.3.1 Market Covered
1.4 Years Considered for the Study
1.5 Currency
1.6 Limitations
1.7 Stakeholders
2 Research Methodology (Page No. - 19)
2.1 Secondary Data
2.1.1 Secondary Sources
2.2 Primary Data
2.2.1 Primary Sources
2.3 Market Size Estimation
2.3.1 Bottom-Up Approach
2.3.2 Top-Down Approach
2.4 Data Triangulation Methodology
2.5 Assumptions for the Study
3 Executive Summary (Page No. - 27)
4 Premium Insights (Page No. - 30)
4.1 Biosimilars Market Overview
4.2 Asia: Biosimilars Market, By Type of Product
4.3 Biosimilars Market, By Region
4.4 Geographical Snapshot: Biosimilars Market (Major Countries)
5 Market Overview (Page No. - 34)
5.1 Introduction
5.2 Market Dynamics
5.2.1 Drivers
5.2.1.1 Increasing Demand for Biosimilar Drugs Due to Their Cost-Effectiveness
5.2.1.2 Rising Incidence of Chronic Diseases
5.2.1.3 Strategic Collaborations Resulting in Enhanced Productivity and Clinical Trial Activities for Biosimilars
5.2.2 Restraints
5.2.2.1 Complexities in Manufacturing
5.2.2.2 Innovative Strategies By Biologic Drug Manufacturers
5.2.3 Opportunities
5.2.3.1 Growth Opportunities in Emerging Markets
5.2.3.2 New Indications and Patent Expiry of Biologic Products
5.2.4 Challenges
5.2.4.1 Stringent Regulatory Requirements to Adversely Affect Investments in Biosimilars
6 Regulatory Outlook (Page No. - 41)
6.1 North America
6.1.1 US
6.1.2 Canada
6.2 Europe
6.3 Asia Pacific
6.3.1 China
6.3.2 India
6.3.3 Japan
6.3.4 South Korea
6.4 Rest of the World
6.4.1 Brazil
6.4.2 Mexico
6.4.3 Argentina
6.4.4 Saudi Arabia
7 Biosimilars Market, By Product (Page No. - 45)
7.1 Introduction
7.2 Recombinant Non-Glycosylated Proteins
7.2.1 Recombinant Human Growth Hormone (RHGH)
7.2.2 Granulocyte Colony-Stimulating Factor (Filgrastim)
7.2.3 Insulin
7.2.4 Interferons
7.2.4.1 Interferon-Beta
7.2.4.2 Interferon-Alpha
7.3 Recombinant Glycosylated Proteins
7.3.1 Erythropoietin (EPO)
7.3.2 Monoclonal Antibodies (MABS)
7.3.2.1 Infliximab
7.3.2.2 Rituximab
7.3.2.3 Adalimumab
7.3.2.4 Other Monoclonal Antibodies
7.3.3 Follitropin
7.4 Recombinant Peptides
7.4.1 Glucagon
7.4.2 Calcitonin
8 Biosimilars Market, By Type of Manufacturing (Page No. - 66)
8.1 Introduction
8.2 In-House Manufacturing
8.3 Contract Manufacturing
9 Biosimilars Market, By Disease (Page No. - 70)
9.1 Introduction
9.2 Oncology
9.3 Chronic Diseases
9.4 Autoimmune Diseases
9.5 Blood Disorders
9.6 Growth Hormone Deficiency
9.7 Infectious Diseases
9.8 Other Diseases
10 Biosimilars Market, By Region (Page No. - 79)
10.1 Introduction
10.2 North America
10.2.1 US
10.2.2 Canada
10.3 Europe
10.3.1 Germany
10.3.2 France
10.3.3 UK
10.3.4 Italy
10.3.5 Spain
10.3.6 Rest of Europe
10.4 Asia
10.4.1 India
10.4.2 China
10.4.3 South Korea
10.4.4 Japan
10.4.5 Rest of Asia
10.5 Rest of the World (RoW)
10.5.1 Latin America
10.5.2 Pacific and Oceania
10.5.3 Middle East and Africa
11 Competitive Landscape (Page No. - 143)
11.1 Overview
11.2 Market Share Analysis, 2016
11.3 Competitive Scenario
11.3.1 Product Launches and Product Approvals
11.3.2 Partnerships, Collaborations, and Agreements
11.3.3 Acquisitions
11.3.4 Expansions
12 Company Profiles (Page No. - 148)
(Introduction, Products & Services, Strategy, & Analyst Insights, Developments, MnM View)*
12.1 Sandoz
12.2 Pfizer
12.3 Teva Pahrmaceutical
12.4 Celltrion
12.5 Biocon
12.6 Amgen
12.7 Samsung Biologics
12.8 Mylan
12.9 Dr. Reddy's Laboratories
12.10 Stada Arzneimittel AG
*Details on Marketsandmarkets View, Introduction, Product & Services, Strategy, & Analyst Insights, New Developments Might Not Be Captured in Case of Unlisted Companies.
13 Appendix (Page No. - 170)
13.1 Insights of Industry Experts
13.2 Discussion Guide
13.3 Knowledge Store: Marketsandmarkets Subscription Portal
13.4 Introducing RT: Real-Time Market Intelligence
13.5 Available Customizations
13.6 Related Reports
13.7 Author Details
List of Tables (176 Tables)
Table 1 Major Collaborations in the Biosimilars Market (20152018)
Table 2 List of Key Biologics Under the Threat of Patent Expiry
Table 3 Status of Regulatory Pathway in North America
Table 4 Substitution Status in European Countries
Table 5 Status of Regulatory Pathway in Asia Pacific
Table 6 Status of Regulatory Pathway in the RoW
Table 7 Biosimilars Market, By Product, 20162023 (USD Million)
Table 8 Biosimilars Market for Recombinant Non-Glycosylated Proteins, By Type, 20162023 (USD Million)
Table 9 Biosimilars Market for Recombinant Non-Glycosylated Proteins, By Region, 20162023 (USD Million)
Table 10 Biosimilars Market for Recombinant Human Growth Hormone, By Region, 20162023 (USD Million)
Table 11 List of Approved Biosimilars for Granulocyte Colony-Stimulating Factor Products From 2013 to 2016
Table 12 Biosimilars Market for Granulocyte Colony-Stimulating Factor, By Region, 20162023 (USD Million)
Table 13 Biosimilars Market for Insulin, By Region, 20162023 (USD Million)
Table 14 Biosimilars Market for Interferons, By Type, 20162023 (USD Million)
Table 15 Biosimilars Market for Interferons, By Region, 20162023 (USD Million)
Table 16 Biosimilars Market for Interferon-Beta , By Region, 20162023 (USD Million)
Table 17 Biosimilars Market for Interferon-Alpha, By Region, 20162023 (USD Million)
Table 18 Biosimilars Market for Recombinant Glycosylated Proteins, By Type, 20162023 (USD Billion)
Table 19 List of Approved Biosimilars for Erythropoietin
Table 20 Biosimilars Market for Erythropoietin, By Region, 20162023 (USD Million)
Table 21 Biosimilars Market for Monoclonal Antibodies, By Type, 20162023 (USD Billion)
Table 22 Biosimilars Market for Monoclonal Antibodies, By Region, 20162023 (USD Million)
Table 23 Pipeline of Inflximab
Table 24 Biosimilars Market for Inflximab, By Region, 20162023 (USD Million)
Table 25 Pipeline of Rituximab
Table 26 Biosimilars Market for Rituximab, By Region, 20162023 (USD Million)
Table 27 Pipeline of Adlimumab
Table 28 Biosimilars Market for Adalimumab, By Region, 20162023 (USD Million)
Table 29 Pipeline of Other Monoclonal Antibodies
Table 30 Biosimilars Market for Other Monoclonal Antibodies, By Region, 20162023 (USD Million)
Table 31 Biosimilars Market for Follitropin, By Region, 20162023 (USD Million)
Table 32 Biosimilars Market for Recombinant Peptides, By Type, 20162023 (USD Million)
Table 33 Biosimilars Market for Recombinant Peptides, By Region, 20162023 (USD Million)
Table 34 Biosimilars Market for Glucagon, By Region, 20162023 (USD Million)
Table 35 Biosimilars Market for Calcitonin, By Region, 20162023 (USD Million)
Table 36 Biosimilars Market, By Manufacturing Type, 20162023 (USD Million)
Table 37 Biosimilars Market for In-House Manufacturing, By Region, 20162023 (USD Billion)
Table 38 Biosimilars Market for Contract Manufacturing, By Region, 20162023 (USD Million)
Table 39 Biosimilars Market, By Disease, 20162023 (USD Million)
Table 40 Biosimilars Market for Oncology, By Region, 20162023 (USD Million)
Table 41 Biosimilars Market for Chronic Diseases, By Region, 20162023 (USD Million)
Table 42 Biosimilars Market for Autoimmune Diseases, By Region, 20162023 (USD Million)
Table 43 Biosimilars Market for Blood Disorders, By Region, 20162023 (USD Million)
Table 44 Biosimilars Market for Growth Hormone Deficiency, By Region, 20162023 (USD Million)
Table 45 Biosimilars Market for Infectious Diseases, By Region, 20162023 (USD Million)
Table 46 Biosimilars Market for Other Diseases, By Region, 20162023 (USD Million)
Table 47 Biosimilars Market, By Region, 20162023 (USD Million)
Table 48 North America: Biosimilars Market, By Country, 20162023 (USD Million)
Table 49 North America: Biosimilars Market, By Product, 20162023 (USD Million)
Table 50 North America: Biosimilars Market for Recombinant Non-Glycosylated Proteins, By Type, 20162023 (USD Million)
Table 51 North America: Biosimilars Market for Recombinant Glycosylated Proteins, By Type, 20162023 (USD Million)
Table 52 North America: Biosimilars Market for Monoclonal Antibodies, By Type, 20162023 (USD Million)
Table 53 North America: Biosimilars Market for Recombinant Peptides, By Type, 20162023 (USD Million)
Table 54 North America: Biosimilars Market, By Manufacturing Type, 20162023 (USD Million)
Table 55 North America: Biosimilars Market, By Disease, 20162023 (USD Million)
Table 56 List of Biosimilars Approved in the Us
Table 57 US: Biosimilars Market, By Product, 20162023 (USD Million)
Table 58 US: Biosimilars Market for Recombinant Non-Glycosylated Proteins, By Type, 20162023 (USD Million)
Table 59 US: Biosimilars Market for Recombinant Glycosylated Proteins, By Type, 20162023 (USD Million)
Table 60 US: Biosimilars Market for Monoclonal Antibodies, By Type, 20162023 (USD Million)
Table 61 US: Biosimilars Market, By Manufacturing Type, 20162023 (USD Million)
Table 62 US: Biosimilars Market, By Disease, 20162023 (USD Million)
Table 63 List of Biosimilars Approved in Canada
Table 64 Canada: Biosimilars Market, By Product, 20162023 (USD Million)
Table 65 Canada: Biosimilars Market for Recombinant Non-Glycosylated Proteins, By Type, 20162023 (USD Million)
Table 66 Canada: Biosimilars Market for Recombinant Glycosylated Proteins, By Type, 20162023 (USD Million)
Table 67 Canada: Biosimilars Market for Monoclonal Antibodies, By Type, 20162023 (USD Million)
Table 68 Canada: Biosimilars Market for Recombinant Peptides, By Type, 20162023 (USD Million)
Table 69 Canada: Biosimilars Market, By Manufacturing Type, 20162023 (USD Million)
Table 70 Canada: Biosimilars Market, By Disease, 20162023 (USD Million)
Table 71 List of Biosimilars Approved in Europe
Table 72 Europe: Biosimilars Market, By Country, 20162023 (USD Million)
Table 73 Europe: Biosimilars Market, By Product, 20162023 (USD Million)
Table 74 Europe: Biosimilars Market for Recombinant Non-Glycosylated Proteins, By Type, 20162023 (USD Million)
Table 75 Europe: Biosimilars Market for Recombinant Glycosylated Proteins, By Type, 20162023 (USD Million)
Table 76 Europe: Biosimilars Market for Recombinant Peptides, By Type, 20162023 (USD Million)
Table 77 Europe: Biosimilars Market, By Manufacturing Type, 20162023 (USD Million)
Table 78 Europe: Biosimilars Market, By Disease, 20162023 (USD Million)
Table 79 Germany: Biosimilars Market, By Product, 20162023 (USD Million)
Table 80 Germany: Biosimilars Market for Recombinant Glycosylated Proteins, By Type, 20162023 (USD Million)
Table 81 Germany: Biosimilars Market for Recombinant Peptides, By Type, 20162023 (USD Million)
Table 82 Germany: Biosimilars Market, By Manufacturing Type, 20162023 (USD Million)
Table 83 Germany: Biosimilars Market, By Disease, 20162023 (USD Million)
Table 84 France: Biosimilars Market, By Product, 20162023 (USD Million)
Table 85 France: Biosimilars Market for Recombinant Glycosylated Proteins, By Type, 20162023 (USD Million)
Table 86 France: Biosimilars Market for Recombinant Peptides, By Type, 20162023 (USD Million)
Table 87 France: Biosimilars Market, By Manufacturing Type, 20162023 (USD Million)
Table 88 France: Biosimilars Market, By Disease, 20162023 (USD Million)
Table 89 List of Biosimilars in the UK
Table 90 UK: Biosimilars Market, By Product, 20162023 (USD Million)
Table 91 UK: Biosimilars Market for Recombinant Glycosylated Proteins, By Type, 20162023 (USD Million)
Table 92 UK: Biosimilars Market for Recombinant Peptides, By Type, 20162023 (USD Million)
Table 93 UK: Biosimilars Market, By Manufacturing Type, 20162023 (USD Million)
Table 94 UK: Biosimilars Market, By Disease, 20162023 (USD Million)
Table 95 Italy: Biosimilars Market, By Product, 20162023 (USD Million)
Table 96 Italy: Biosimilars Market for Recombinant Glycosylated Proteins, By Type, 20162023 (USD Million)
Table 97 Italy: Biosimilars Market for Recombinant Peptides, By Type, 20162023 (USD Million)
Table 98 Italy: Biosimilars Market, By Manufacturing Type, 20162023 (USD Million)
Table 99 Italy: Biosimilars Market, By Disease, 20162023 (USD Million)
Table 100 Spain: Biosimilars Market, By Product, 20162023 (USD Million)
Table 101 Spain: Biosimilars Market for Recombinant Glycosylated Proteins, By Type, 20162023 (USD Million)
Table 102 Spain: Biosimilars Market for Recombinant Peptides, By Type, 20162023 (USD Million)
Table 103 Spain: Biosimilars Market, By Manufacturing Type, 20162023 (USD Million)
Table 104 Spain: Biosimilars Market, By Disease, 20162023 (USD Million)
Table 105 RoE: Biosimilars Market, By Product, 20162023 (USD Million)
Table 106 RoE: Biosimilars Market for Recombinant Glycosylated Proteins, By Type, 20162023 (USD Million)
Table 107 RoE: Biosimilars Market for Recombinant Peptides, By Type, 20162023 (USD Million)
Table 108 RoE: Biosimilars Market, By Manufacturing Type, 20162023 (USD Million)
Table 109 RoE: Biosimilars Market, By Disease, 20162023 (USD Million)
Table 110 Asia: Biosimilars Market, By Country, 20162023 (USD Million)
Table 111 Asia: Biosimilars Market, By Product, 20162023 (USD Million)
Table 112 Asia: Biosimilars Market for Recombinant Non-Glycosylated Proteins, By Type, 20162023 (USD Million)
Table 113 Asia: Biosimilars Market for Interferons, By Type, 20162023 (USD Million)
Table 114 Asia: Biosimilars Market for Recombinant Glycosylated Proteins, By Type, 20162023 (USD Million)
Table 115 Asia: Biosimilars Market for Monoclonal Antibodies, By Type, 20162023 (USD Million)
Table 116 Asia: Biosimilars Market for Recombinant Peptides, By Type, 20162023 (USD Million)
Table 117 Asia: Biosimilars Market, By Manufacturing Type, 20162023 (USD Million)
Table 118 Asia: Biosimilars Market, By Disease, 20162023 (USD Million)
Table 119 Biologics Approved and Marketed in India
Table 120 India: Biosimilars Market, By Product, 20162023 (USD Million)
Table 121 India: Biosimilars Market for Recombinant Non-Glycosylated Proteins, By Type, 20162023 (USD Million)
Table 122 India: Biosimilars Market for Interferons, By Type, 20162023 (USD Million)
Table 123 India: Biosimilars Market for Recombinant Glycosylated Proteins, By Type, 20162023 (USD Million)
Table 124 India: Biosimilars Market for Monoclonal Antibodies, By Type, 20162023 (USD Million)
Table 125 India: Biosimilars Market for Recombinant Peptides, By Type, 20162023 (USD Million)
Table 126 India: Biosimilars Market, By Manufacturing Type, 20162023 (USD Million)
Table 127 India: Biosimilars Market, By Disease, 20162023 (USD Million)
Table 128 China: Biosimilars Market, By Product, 20162023 (USD Million)
Table 129 China: Biosimilars Market for Recombinant Non-Glycosylated Proteins, By Type, 20162023 (USD Million)
Table 130 China: Biosimilars Market for Interferons, By Type, 20162023 (USD Million)
Table 131 China: Biosimilars Market for Recombinant Glycosylated Proteins, By Type, 20162023 (USD Million)
Table 132 China: Biosimilars Market for Monoclonal Antibodies, By Type, 20162023 (USD Million)
Table 133 China: Biosimilars Market for Recombinant Peptides, By Type, 20162023 (USD Million)
Table 134 China: Biosimilars Market, By Manufacturing Type, 20162023 (USD Million)
Table 135 China: Biosimilars Market, By Disease, 20162023 (USD Million)
Table 136 List of Biosimilars Approved in South Korea
Table 137 South Korea: Biosimilars Market, By Product, 20162023 (USD Million)
Table 138 South Korea: Biosimilars Market for Recombinant Non-Glycosylated Proteins, By Type, 20162023 (USD Million)
Table 139 South Korea: Biosimilars Market for Recombinant Glycosylated Proteins, By Type, 20162023 (USD Million)
Table 140 South Korea: Biosimilars Market for Monoclonal Antibodies, By Type, 20162023 (USD Million)
Table 141 South Korea: Biosimilars Market, By Manufacturing Type, 20162023 (USD Million)
Table 142 South Korea: Biosimilars Market, By Disease, 20162023 (USD Million)
Table 143 List of Biosimilars Approved in Japan
Table 144 Japan: Biosimilars Market, By Product, 20162023 (USD Million)
Table 145 Japan: Biosimilars Market for Recombinant Non-Glycosylated Proteins, By Type, 20162023 (USD Million)
Table 146 Japan: Biosimilars Market for Recombinant Glycosylated Proteins, By Type, 20162023 (USD Million)
Table 147 Japan: Biosimilars Market for Monoclonal Antibodies, By Type, 20162023 (USD Million)
Table 148 Japan: Biosimilars Market for Recombinant Peptides, By Type, 20162023 (USD Million)
Table 149 Japan: Biosimilars Market, By Manufacturing Type, 20162023 (USD Million)
Table 150 Japan: Biosimilars Market, By Disease, 20162023 (USD Million)
Table 151 RoA: Biosimilars Market, By Product, 20162023 (USD Million)
Table 152 RoA: Biosimilars Market for Recombinant Non-Glycosylated Proteins, By Type, 20162023 (USD Million)
Table 153 RoA: Biosimilars Market for Interferons, By Type, 20162023 (USD Million)
Table 154 RoA: Biosimilars Market for Recombinant Glycosylated Proteins, By Type, 20162023 (USD Million)
Table 155 RoA: Biosimilars Market for Monoclonal Antibodies, By Type, 20162023 (USD Million)
Table 156 RoA: Biosimilars Market for Recombinant Peptides, By Type, 20162023 (USD Million)
Table 157 RoA: Biosimilars Market, By Manufacturing Type, 20162023 (USD Million)
Table 158 RoA: Biosimilars Market, By Disease, 20162023 (USD Million)
Table 159 RoW: Biosimilars Market, By Region, 20162023 (USD Million)
Table 160 RoW: Biosimilars Market, By Product, 20162023 (USD Million)
Table 161 RoW: Biosimilars Market for Recombinant Non-Glycosylated Proteins, By Type, 20162023 (USD Million)
Table 162 RoW: Biosimilars Market for Recombinant Glycosylated Proteins, By Type, 20162023 (USD Million)
Table 163 RoW: Biosimilars Market for Recombinant Peptides, By Type, 20162023 (USD Million)
Table 164 RoW: Biosimilars Market, By Manufacturing Type, 20162023 (USD Million)
Table 165 RoW: Biosimilars Market, By Disease, 20162023 (USD Million)
Table 166 List of Similar Biotherapeutic Products Approved in Latin America
Table 167 Latin America : Biosimilars Market, By Product, 20162023 (USD Million)
Table 168 List of Biosimilars Approved in Australia
Table 169 List of Biosimilars Approved in New Zealand
Table 170 Pacific and Oceania: Biosimilars Market, By Product, 20162023 (USD Million)
Table 171 Middle East and Africa: Biosimilars Market, By Product, 20162023 (USD Million)
Table 172 The Companys Biosimilar in Pipeline are Listed Below
Table 173 The Companys Biosimilar in Pipeline are Listed Below
Table 174 The Companys Biosimilar in Pipeline are Listed Below
Table 175 The Companys Biosimilar in Pipeline are Listed Below
Table 176 The Companys Biosimilar in Pipeline are Listed Below
List of Figures (37 Figures)
Figure 1 Research Methodology
Figure 2 Breakdown of Primary Interviews
Figure 3 Bottom-Up Approach
Figure 4 Top-Down Approach
Figure 5 Data Triangulation
Figure 6 Biosimilars Market, By Product, 2018 vs 2023 (USD Million)
Figure 7 Biosimilars Market, By Manufacturing Type, 2018 vs 2023 (USD Million)
Figure 8 Biosimilars Market, By Disease, 2018 vs 2023 (USD Million)
Figure 9 Biosimilars Market, By Region, 2018 vs 2023 (USD Billion)
Figure 10 Rising Incidence of Chronic Diseases to Drive the Growth of the Market
Figure 11 Recombinant Glycosylated Protiens Segment to Account for the Largest Market Share in 2017
Figure 12 North America Accounted for the Largest Share in 2017
Figure 13 India to Register the Highest CAGR During the Forecast Period
Figure 14 Biosimilars Market: Drivers, Restraints, Opportunities, & Challenges
Figure 15 Increasing Geriatric Population, By Region, 2015 vs 2030
Figure 16 Global Incidence of Diabetes, By Region, 2017 vs 2045
Figure 17 Biosimilars Market, By Product, 2018 vs 2023 (USD Million)
Figure 18 In-House Manufacturing Segment to Dominate the Biosimilars Market in 2018
Figure 19 Oncology Segment to Dominate the Biosimilars Market in 2018
Figure 20 Asia to Register the Highest Growth Rate in the Biosimilars Market During the Forecast Period
Figure 21 North America: Biosimilars Market Snapshot
Figure 22 Cancer Incidence in Canada
Figure 23 Europe: Biosimilars Market Snapshot
Figure 24 Asia: Biosimilars Market Snapshot
Figure 25 RoW: Biosimilars Market Snapshot
Figure 26 Key Developments of Major Players From 2015 to 2018
Figure 27 Global Biosimilars Market Share Analysis, By Key Player 2016
Figure 28 Sandoz: Company Snapshot
Figure 29 Pfizer: Company Snapshot
Figure 30 Teva Pharmaceutical: Company Snapshot
Figure 31 Celltrion: Company Snapshot
Figure 32 Biocon: Company Snapshot
Figure 33 Amgen: Company Snapshot
Figure 34 Samsung Biologics: Company Snapshot
Figure 35 Mylan: Company Snapshot
Figure 36 Dr. Reddy's Laboratories: Company Snapshot
Figure 37 Stada Arzneimittel AG: Company Snapshot
The global biosimilars market is expected to reach USD 23.63 Billion by 2023 from USD 5.95 Billion in 2018, at a CAGR of 31.7%. Market growth is primarily driven by the increasing demand for biosimilar drugs due to their cost-effectiveness, increasing incidences of chronic diseases, and strategic collaborations resulting in enhanced productivity and clinical trial activities.
The global biosimilars market is segmented by product, type of manufacturing, disease, and region. The products in biosimilars market include non-glycosylated proteins, recombinant glycosylated proteins, and recombinant peptides. The non-glycosylated proteins segment accounted for the largest market share of the market in 2017, however recombinant glycosylated proteins are expected to hold the largest share of the market during the forecast period.
On the basis of type of manufacturing, the market is classified into in-house manufacturing and contract manufacturing. The in-house manufacturing segment accounted for the largest share in 2017. Many players in the biosimilars market prefer the in-house method of manufacturing as they can develop biosimilars in their own laboratories and this type of manufacturing eliminates shipping and delivery costs.
On the basis of diseases, the market is classified into oncology, chronic diseases, autoimmune diseases, blood disorders, growth hormone deficiency, infectious diseases, and other diseases. The blood disorder segment accounted for the largest share of the market in 2017. The rising incidence of blood disorders across the globe, low cost of biosimilars compared to biologics, and the rising pressure to reduce healthcare expenditure are major factors contributing to the growth of this segment.
The market was dominated by Europe in 2017. Europe is also expected to hold the largest share of the global market during the forecast period. However, Asia is expected to witness the highest CAGR from 2018 to 2023. A number of factors, such as the patent expiry of biologic products & the launch of new biosimilars, rising incidence of chronic disorders, and the emergence of new market participants are expected to propel market growth in the region. Growth in the geriatric population and the subsequent increase in the incidence of age-related disorders and chronic disorders is also expected to increase the demand for biosimilars in Europe.
Pfizer (US), Sandoz International (Germany), Teva Pharmaceuticals (Israel), Amgen (US), Biocon (India), Dr. Reddys Laboratories (India), Celltrion (South Korea), and Samsung Biologics (South Korea) are some of the key players in the global biosimilars market.
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
